Title:
PEPTIDE FOR INHIBITING EB VIRUS, DNA ENCODING PEPTIDE, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/073234
Kind Code:
A1
Abstract:
The present invention belongs to the field of biomedicine, and specifically relates to a peptide for inhibiting the Epstein-Barr virus, DNA encoding the peptide, and the use thereof. By means of using the peptide, the replication of the Epstein-Barr virus can be effectively inhibited, such that diseases related to the Epstein-Barr virus can prevented and/or treated.
More Like This:
Inventors:
GAO SONG (CN)
HE HUIPING (CN)
LUO MENG (CN)
CAO YULU (CN)
OU JUNYING (CN)
YU BING (CN)
HE HUIPING (CN)
LUO MENG (CN)
CAO YULU (CN)
OU JUNYING (CN)
YU BING (CN)
Application Number:
PCT/CN2020/120203
Publication Date:
April 14, 2022
Filing Date:
October 10, 2020
Export Citation:
Assignee:
SUN YAT SEN UNIV CANCER CENTER (CN)
International Classes:
A61K38/16; C07K14/00; A61P31/22; A61P35/00; C07K19/00; C12N15/11
Domestic Patent References:
| WO2020074708A1 | 2020-04-16 |
Foreign References:
| CN103328003A | 2013-09-25 | |||
| US6518013B1 | 2003-02-11 |
Other References:
DATABASE PROTEIN 1 December 2020 (2020-12-01), ANONYMOUS : "Chain H, Tegument protein UL51 homolog", XP055919071, retrieved from NCBI Database accession no. 6LQO_H
DATABASE PROTEIN 2 June 2021 (2021-06-02), ANONYMOUS : "RecName:Full=Tegument protein UL51 homolog", XP055919080, retrieved from NCBI Database accession no. P0CK50
JOHANNSEN, E. ET AL.: "Proteins of purified Epstein–Barr virus", PNAS, vol. 101, no. 46, 16 November 2004 (2004-11-16), XP002337075, DOI: 10.1073/pnas.0407320101
YANAGI YUSUKE, MASUD H., WATANABE TAKAHIRO, SATO YOSHITAKA, GOSHIMA FUMI, KIMURA HIROSHI, MURATA TAKAYUKI: "Initial Characterization of the Epstein–Barr Virus BSRF1 Gene Product", VIRUSES, vol. 11, no. 3, 21 March 2019 (2019-03-21), XP055919082, DOI: 10.3390/v11030285
SERRANO-SOLIS, V. ET AL.: "Prediction of MicroRNAs in the Epstein–Barr Virus Reveals Potential Targets for the Viral Self-Regulation", INDIAN JOURNAL OF MICROBIOL, vol. 59, no. 1, 28 December 2018 (2018-12-28), XP036669367, DOI: 10.1007/s12088-018-0775-4
MASUD H. M. ABDULLAH AL, YANAGI YUSUKE, WATANABE TAKAHIRO, SATO YOSHITAKA, KIMURA HIROSHI, MURATA TAKAYUKI: "Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity", MICROORGANISMS, vol. 7, no. 12, 16 December 2019 (2019-12-16), XP055919083, DOI: 10.3390/microorganisms7120705
DATABASE PROTEIN 2 June 2021 (2021-06-02), ANONYMOUS : "RecName:Full=Tegument protein UL51 homolog", XP055919080, retrieved from NCBI Database accession no. P0CK50
JOHANNSEN, E. ET AL.: "Proteins of purified Epstein–Barr virus", PNAS, vol. 101, no. 46, 16 November 2004 (2004-11-16), XP002337075, DOI: 10.1073/pnas.0407320101
YANAGI YUSUKE, MASUD H., WATANABE TAKAHIRO, SATO YOSHITAKA, GOSHIMA FUMI, KIMURA HIROSHI, MURATA TAKAYUKI: "Initial Characterization of the Epstein–Barr Virus BSRF1 Gene Product", VIRUSES, vol. 11, no. 3, 21 March 2019 (2019-03-21), XP055919082, DOI: 10.3390/v11030285
SERRANO-SOLIS, V. ET AL.: "Prediction of MicroRNAs in the Epstein–Barr Virus Reveals Potential Targets for the Viral Self-Regulation", INDIAN JOURNAL OF MICROBIOL, vol. 59, no. 1, 28 December 2018 (2018-12-28), XP036669367, DOI: 10.1007/s12088-018-0775-4
MASUD H. M. ABDULLAH AL, YANAGI YUSUKE, WATANABE TAKAHIRO, SATO YOSHITAKA, KIMURA HIROSHI, MURATA TAKAYUKI: "Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity", MICROORGANISMS, vol. 7, no. 12, 16 December 2019 (2019-12-16), XP055919083, DOI: 10.3390/microorganisms7120705
Attorney, Agent or Firm:
IP MARCH (CN)
Download PDF:
Previous Patent: BATTERY CELL HOLDER, BATTERY CELL MODULE, AND BATTERY PACK
Next Patent: DISPLAY DEVICE AND METHOD FOR FABRICATING DISPLAY DEVICE
Next Patent: DISPLAY DEVICE AND METHOD FOR FABRICATING DISPLAY DEVICE